Decoy Therapeutics (FRA:FP11) Other Operating Expense: €-0.20 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FP11 Decoy Therapeutics Inc FRA:FP11
23 GF Score
Price €5.23
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics Other Operating Expense?

Decoy Therapeutics FRA:FP11 23 Other Operating Expense is €-0.20 Mil as of Jun. 2026. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Decoy Therapeutics's Other Operating Expense for the three months ended in Jun. 2026 was €-0.20 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.20 Mil.

Decoy Therapeutics's quarterly Other Operating Expense declined from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil) and declined from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€-0.20 Mil).

Decoy Therapeutics's annual Other Operating Expense increased from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Decoy Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Decoy Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics Other Operating Expense Chart

Decoy Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.63 -0.00 -0.00 0.00 -0.00

Decoy Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.20
FRA:FP11
23GF Score
Decoy Therapeutics Inc FRA:FP11
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Decoy Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €-0.20 Mil mean?
Decoy Therapeutics (FRA:FP11) has a Other Operating Expense of €-0.20 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Decoy Therapeutics and its competitors.
Is Decoy Therapeutics' Other Operating Expense too high?
Decoy Therapeutics' current Other Operating Expense is €-0.20 Mil. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' Other Operating Expense compare to PKTX and CASIF?
Decoy Therapeutics' Other Operating Expense of €-0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Decoy Therapeutics and its competitors. Decoy Therapeutics's current Other Operating Expense is €-0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current Other Operating Expense of €-0.20 Mil. The current Other Operating Expense is €-0.20 Mil. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current Other Operating Expense is €-0.20 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Other Exchanges DCOY:USA
Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for FRA:FP11

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price